IP Library Granted Patent US 8,975,040
Granted Patent B2
US 8,975,040 · App. 13/974,655 · Granted Mar 10, 2015

Methods and vectors for generating asialylated immunoglobulins

Inventors: Michael Naso (Spring House, PA); T. Shantha Raju (Spring House, PA); Bernard Scallon (Spring House, PA)
Assignee: Janssen Biotech, Inc.
C07K16/241C07K16/00C07K2317/41C07K2317/72C07K2317/732C12P21/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,975,040
App. No.
13/974,655
Granted
Mar 10, 2015
Kind
B2
Abstract

The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the FcγRI, FcγRIIA, and FcγRIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.

Claims (6)

1. A method for controlling the properties of an antibody expressed in a cell line, comprising reducing the sialylation of the oligosaccharides in the Fc region by transfecting the cell line with a vector encoding a catalytic domain of Arthrobacter ureafaciens sialidase enzyme, wherein the antibody expressed comprises a reduced amount of sialic acid residues.

2. The method of claim 1 , wherein the properties of the antibody controlled are the avidity of the antibody for multiply localized target proteins; the affinity for one or more of the Fc gamma receptors of FcγRI, FcγRIIA, and FcγRIIIA; ADCC activity; macrophage or monocyte activation; and serum half-life.

3. The method of claim 1 , wherein the mammalian cell line is selected from the group consisting of COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, YB2/0 or Y3, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

4. The method of claim 3 , wherein the antibody is an anti-TNFα antibody and the cell line is C168M.

5. The method of claim 1 , wherein the antibody has a binding domain specific for a target, said target being an immobilized target.

6. The method of claim 1 , wherein the antibody has a binding domain specific for a target, said target being is expressed on the surface of a cell.

Continuity (3)
Division 12521417
Provisional Application 60882301 · Dec 28, 2006
Related Publication 20140057319A1 · Feb 27, 2014